FDA releases Ariflo briefing documents

Deliberations at Friday's meeting of FDA's Pulmonary-Allergy Drugs Advisory Committee will focus on the clinical relevance of the efficacy demonstrated in trials of GlaxoSmithKline's Ariflo cilomilast, and on the adequacy of the safety database,